2020
DOI: 10.3233/jpd-202045
|View full text |Cite
|
Sign up to set email alerts
|

Minority Enrollment in Parkinson’s Disease Clinical Trials: Meta-Analysis and Systematic Review of Studies Evaluating Treatment of Neuropsychiatric Symptoms

Abstract: Background: Randomized clinical trials (RCTs) in Parkinson’s disease (PD) have historically enrolled a low number of underrepresented minorities, lessening the generalizability of therapeutic developments. Although there are racial disparities in PD, little is known regarding neuropsychiatric symptoms and other nonmotor manifestations across all races/ethnicities. Objective: To assess minority participation in PD trials evaluating the treatment of neuropsychiatric symptoms and explore underlying reasons. Metho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
17
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 16 publications
(19 citation statements)
references
References 36 publications
0
17
2
Order By: Relevance
“…Enabling participation in clinical trials for people with PD is necessary, particularly those who are older and with more co-morbidities. Moreover, ethnic minority group enrolment in clinical trials for PD is very low [58] and women are also less likely to enrol [59]; both groups have been historically underrepresented in clinical trials. The INCLUDE guidelines aim to reduce barriers and challenges to trial participation and improve engagement with research for under-served groups.…”
Section: Communication and Management Of Study Closurementioning
confidence: 99%
“…Enabling participation in clinical trials for people with PD is necessary, particularly those who are older and with more co-morbidities. Moreover, ethnic minority group enrolment in clinical trials for PD is very low [58] and women are also less likely to enrol [59]; both groups have been historically underrepresented in clinical trials. The INCLUDE guidelines aim to reduce barriers and challenges to trial participation and improve engagement with research for under-served groups.…”
Section: Communication and Management Of Study Closurementioning
confidence: 99%
“…6,7 Nevertheless, studies have shown that participants' race and ethnicity are often not reported in clinical trial results. [8][9][10][11] Studies evaluating enrollment in pediatric clinical trials for hematologic malignancies have demonstrated that Black/ African American participants 12,13 and Hispanic/Latino participants 14,15 have been underrepresented. In a 2003 study, Walsh and Ross 16 reviewed articles published in 3 general pediatric journals during a single year and demonstrated that Black participants were included more than expected and White participants and Hispanic/Latino participants were included less than expected in clinical trials; Black/African American and Hispanic children were underrepresented in therapeutic research.…”
mentioning
confidence: 99%
“…Previous studies identify underrepresentation of participants belonging to marginalized racial and ethnic groups in PD trials or even missing data regarding racial and ethnic information in most clinical trials in the United States. 7 , 15 Many reasons for these deficiencies have been hypothesized. As large PD trials are mostly performed in subspecialized movement disorders clinics, persons from marginalized racial and ethnic groups might have lower enrollment rates as they are less likely to be followed by general neurologists or movement disorders specialists.…”
Section: Discussionmentioning
confidence: 99%